SCHEMBL6421348

SCHEMBL6421348

O=c1nc(-c2ccnc(Sc3ccccc3)c2)sc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.52
GABRA1 P14867 1/20 0.52
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
NPSR1 Q6W5P4 5/20 0.41
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 3/20 0.41
LMNA P02545 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 7/20 0.38
RXFP1 Q9HBX9 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956629 0.86 MIF (0.53) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2961592 0.82 MIF (0.62) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2960993 0.80 MIF (0.56) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL13186559 0.77 MIF (0.61) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2956905 0.77 MIF (0.42) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2964289 0.77 MIF (0.52) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2960726 0.76 MIF (0.66) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL1001394 0.76 MIF (0.60) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2959138 0.76 MIF (0.51) MIFGABRA1NPC1RAB9ANPSR1
SCHEMBL2962988 0.76 GABRA1 (0.48) MIFGABRA1NPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 MIF 1/4885GABRA1 3323/4885NPC1 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.